Latest Breaking News On - Gynecologic oncology annual meeting - Page 9 : comparemela.com

Mirvetuximab soravtansine demonstrated efficacy and tolerability in patients with platinum resistant ovarian cancer, according to phase 3 clinical data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

United statesUrsula matulonisOvarian cancer research allianceRivkin foundationHarvard medical schoolClearity foundationDana farber cancer instituteGynecologic oncology annual meetingBlueprint medicinesBrock wilson family chairHarvard medicalPublished march